MC2 Therapeutics A/S announces completion of recruitment in Phase 2 study in moderate-to-severe dry eye disease with MC2-03
POSTED: November 9, 2017
- Completion of patient recruitment meeting randomization target of 264 patients
- Topline results are expected in 2018
Copenhagen, November 9th, 2017 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today ...
READ FULL ARTICLE >
MC2 Therapeutics A/S announces first patient dosed in pivotal US Phase 3 trial in psoriasis vulgaris
POSTED: October 9, 2017
- First patient dosed in the pivotal Phase 3 trial assessing the safety and efficacy of MC2-01 Cream in US
- Topline results are expected in Q3 2018
Copenhagen, October 9th, 2017 – MC2 ...
READ FULL ARTICLE >
MC2 Therapeutics A/S appoints Anders D. Hove and Paul L. Berns to the Board of Directors
POSTED: August 1, 2017
Copenhagen, August, 2017 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company, has appointed Dr. Anders D. Hove and Mr. Paul L. Berns to serve on the Board.
“On ...
READ FULL ARTICLE >
MC2 Therapeutics to present data at the 2017 ARVO Annual Meeting highlighting the therapeutic potential of PAD ® Techno.
POSTED: May 1, 2017
Copenhagen, February 24th, 2017 – MC2 Therapeutics today announced that two abstracts were accepted for poster presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting ...
READ FULL ARTICLE >
